Celcuity Inc Sustainability Reports
Celcuity Inc. is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's principal product candidate is gedatolisib, a pan-PI3K and mTOR inhibitor evaluated for advanced breast cancer treatment.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 25490070W7UU7W2SEY87
FIGI: BBG00HKBW054
3 reports from 2021 to 2024
